Cancer Database’s Cases Indicate 200,000 Missing Cases: What Does It Mean?
“Our concern is that these patients may show up later, potentially at more advanced disease stages,” said Sharon Lum, MD, MBA, chair of the Loma Linda University Health Department of Surgery and the study’s principal investigator.
The study was published today in the Journal of the American Medical Association Surgery. Its authors hope their findings will serve as a reference for those utilizing NCBD data to conduct research, quality reports, and process improvement projects.
Exploring the 200,000 Missing Cases in the Cancer Database
Lum said researchers wanted to alert those using NCBD data from 2020 that all of their reports are going to be altered in some fashion from the disruption in reported cases.
Advertisement
The NCDB, a joint project by the American College of Surgeons Commission on Cancer and the American Cancer Society, is one of the largest cancer registries in the world, representing more than 70% of all cancer cases in the United States. Nearly 1,500 programs accredited by the Commission on Cancer, including Loma Linda University Health, leverage NCBD data to improve the quality of cancer care in the United States, Lum said. She previously served as vice-chair of the Commission on Cancer’s quality integration committee.
Year-over-year since 1989, NCDB data have proven historically reliably stable, Lum says. Yet “the COVID-19 pandemic destabilized usual patterns of cancer care,” study authors wrote.
Lum and researchers from academic and medical institutions across the nation examined all cancer cases added to the NCDB in the years leading up to the pandemic and analyzed the variances in reported cases during 2020 compared to 2018 and 2019. Their research revealed that the monthly decline in cancer cases logged in the NCDB during 2020 correlated with the timing of stay-at-home orders and triage guidelines recommending intentional delays in cancer-related care.
Additionally, Lum says researchers observed less than expected numbers of early-stage diseases in the pandemic’s early months and simultaneously observed more than expected cases of late-stage diseases.
Researchers did not identify any overall patterns in patient demographics to account for the varied differences of observed-to-expected proportions of reported cancer cases, Lum says.
“The differences in expected versus observed cases didn’t happen in the same way across the board for every single cancer site,” Lum says. “There were high levels of variation between different diseases and individual cancer sites.”
The study’s findings provide month-by-month breakdowns of NCDB’s 2020 trends in reported cases, Lum says; the monthly analysis isn’t standardly available to NCDB users and offers valuable insights into details of the year’s progression. The findings call for NCDB users engaged in cancer care quality reporting, process improvement, or research to carefully interpret disease- and program-specific results for 2020 and years to come to account for the disrupted pandemic year data. Study authors recommend users perform their own validation studies before incorporating 2020 data and use disclaimer language in publications using 2020 NCDB data.
“We are alerting the cancer community to look carefully at their institutional data to see how what happened in 2020 could have affected what their reports looked like,” Lum said. “Database users should consider what activities took place in their local and institutional environment that first year of the pandemic.”
Source: Eurekalert
Source link
#Cancer #Databases #Cases #Missing #Cases